Procarbazine hydrochloride in the treatment of brain tumors. Phase 2 study.
D000293:Adolescent; D000328:Adult; D000927:Anticonvulsants / Q000627:therapeutic use; D001254:Astrocytoma / Q000188:drug therapy; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy; D002648:Child; D004569:Electroencephalography; D004806:Ependymoma / Q000188:drug therapy; D005069:Evaluation Studies as Topic; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy; D005910:Glioma / Q000188:drug therapy; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007165:Immunosuppression Therapy; D007970:Leukopenia / Q000139:chemically induced; D008297:Male; D008527:Medulloblastoma / Q000188:drug therapy; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009837:Oligodendroglioma / Q000188:drug therapy; D011344:Procarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011877:Radionuclide Imaging; D013921:Thrombocytopenia / Q000139:chemically induced
D000927:Anticonvulsants; D005938:Glucocorticoids; D011344:Procarbazine